Aldeyra Therapeutics Schedules Webcast and Conference Call to Provide First Quarter 2018 Financial Results
Aldeyra will hold a conference call on
After the live webcast, the event will remain archived on the
Aldeyra Therapeutics is developing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment in late-stage development for dry eye disease and other forms of ocular inflammation. Aldeyra is leveraging its experience in ocular inflammation to develop other product candidates for systemic inflammatory disease. None of Aldeyra's product candidates have been approved for sale in the U.S. or elsewhere.
Tel: +1 781-761-4904 ext. 205
MacDougall Biomedical Communications
News Provided by Acquire Media